Yang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Lixiang Ma
Department of Anatomy, Histology & Embryology, School of Basic Medical Science, Fudan University
3 shared publications - Chenyun Song
Department of Anatomy, Histology & Embryology, School of Basic Medical Science, Fudan University
2 shared publications - Hexige Saiyin
School of Life Sciences, Fudan University
2 shared publications - Qizhi He
Department of Pathology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Tongji University, Shanghai 200092, China
2 shared publications - Xinyu Chen
School of Basic Medical Sciences, Fudan University 1 Department of Anatomy and Histology & Embryology Shanghai
2 shared publications - Andrew P. Hodges
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
1 shared publication
Latest Publications
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
TRAF7 mutations stabilize K/NRAS and hyperactivate MAPK signaling to cause CAFDADD neurodevelopmental defects
The MAPK-ERK1/2 pathway plays a crucial role in neurodevelopment during embryogenesis, and the hyperactivation of this signaling cascade serves as a pathological hallmark for various neurodevelopmental disorders. Germline variants in TRAF7 , encoding a RING-type E3 ubiquitin ligase, are genetically associated with cardiac, facial, and digital anomalies with developmental delay (CAFDADD) syndrome; however, the downstream substrates of TRAF7 and the precise mechanism driving neurodevelopmental defects remain enigmatic. Here, we established a Traf7 R654Q/+ knock-in mouse model and patient-specific induced pluripotent stem cell (iPSC)–derived human cortical organoids (hCOs) carrying the recurrent TRAF7 R655Q mutation. Heterozygous Traf7 R654Q/+ mice exhibited remarkable growth retardation, skeletal abnormalities, and neurobehavioral deficits, whereas mutant hCOs displayed early cortical neurogenesis defects, characterized by premature neural differentiation and a depleted progenitor pool. Mechanistically, biochemical analyses revealed that TRAF7 interacts with KRAS and NRAS to promote their polyubiquitination and subsequent proteasomal degradation, maintaining physiological homeostatic control over the downstream MAPK cascade. CAFDADD-associated TRAF7 variants exert a dominant-negative effect, disrupting WT protein function and causing the posttranslational accumulation of KRAS and NRAS, which fundamentally drives constitutive MAPK-ERK1/2 pathway hyperactivation. Notably, pharmacological inhibition of MEK1/2 with selumetinib suppressed ERK1/2 hyperactivation, partially mitigated aberrant neuroepithelial morphology and neural differentiation in TRAF7 R655Q/+ hCOs, and improved brain-to-body weight ratios in Traf7 R654Q/+ mice. Together, our findings identify TRAF7 as a critical posttranslational regulator of RAS proteostasis during development and uncover a pivotal mechanistic link between impaired RAS ubiquitination and CAFDADD pathogenesis, providing preliminary clinical-front evidence for targeting the MAPK pathway to manage ongoing developmental deficits in TRAF7-associated disorders.
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
TRAF7 mutations stabilize K/NRAS and hyperactivate MAPK signaling to cause CAFDADD neurodevelopmental defects
The MAPK-ERK1/2 pathway plays a crucial role in neurodevelopment during embryogenesis, and the hyperactivation of this signaling cascade serves as a pathological hallmark for various neurodevelopmental disorders. Germline variants in TRAF7 , encoding a RING-type E3 ubiquitin ligase, are genetically associated with cardiac, facial, and digital anomalies with developmental delay (CAFDADD) syndrome; however, the downstream substrates of TRAF7 and the precise mechanism driving neurodevelopmental defects remain enigmatic. Here, we established a Traf7 R654Q/+ knock-in mouse model and patient-specific induced pluripotent stem cell (iPSC)–derived human cortical organoids (hCOs) carrying the recurrent TRAF7 R655Q mutation. Heterozygous Traf7 R654Q/+ mice exhibited remarkable growth retardation, skeletal abnormalities, and neurobehavioral deficits, whereas mutant hCOs displayed early cortical neurogenesis defects, characterized by premature neural differentiation and a depleted progenitor pool. Mechanistically, biochemical analyses revealed that TRAF7 interacts with KRAS and NRAS to promote their polyubiquitination and subsequent proteasomal degradation, maintaining physiological homeostatic control over the downstream MAPK cascade. CAFDADD-associated TRAF7 variants exert a dominant-negative effect, disrupting WT protein function and causing the posttranslational accumulation of KRAS and NRAS, which fundamentally drives constitutive MAPK-ERK1/2 pathway hyperactivation. Notably, pharmacological inhibition of MEK1/2 with selumetinib suppressed ERK1/2 hyperactivation, partially mitigated aberrant neuroepithelial morphology and neural differentiation in TRAF7 R655Q/+ hCOs, and improved brain-to-body weight ratios in Traf7 R654Q/+ mice. Together, our findings identify TRAF7 as a critical posttranslational regulator of RAS proteostasis during development and uncover a pivotal mechanistic link between impaired RAS ubiquitination and CAFDADD pathogenesis, providing preliminary clinical-front evidence for targeting the MAPK pathway to manage ongoing developmental deficits in TRAF7-associated disorders.
- Open Access
- 18 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (6)
Identification of secondary microglial formation centers in the human fetal brain
Microglia migrate from the yolk sac and populate the developing brain. How microglia expand rapidly to meet the microglial demand in fast-expanding human fetal brains remains uncharted. Using thick sections in 5−22–gestational week (gw) brains and super-resolution scanning, we identified a large proliferative microglial aggregate (2.129 mm2) near the lateral ganglionic eminence (>12.5 gw), expanding in Down’s syndrome (DS) (4.767 mm2) and Edwards syndrome (ES) (3.437 mm2) fetal brains. Ki67+ microglia within the aggregates accounted for 26.65% (DS: 38.9%; ES: 46.3%) compared with 6.32% (DS: 6.01%; ES: 5.2%) in scattered microglia. This aggregate region contained a distinct microglial population characterized by the absence of phagocytic structures and complex processes, high CSF-1R expression, abundant IL-34+ cells, and some SPP1+ bipolar microglia. We termed this structure the secondary microglial formation center (SMFC). Chimeric microglia–human cortical organoids recapitulated the SMFC in an IL-34– and CSF-1R–dependent manner, indicating that the human SMFC may compensate for the microglial shortage during the fastest expansion period.
- 18 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (6)
Open AccessIdentification of secondary microglial formation centers in the human fetal brain
Microglia migrate from the yolk sac and populate the developing brain. How microglia expand rapidly to meet the microglial demand in fast-expanding human fetal brains remains uncharted. Using thick sections in 5−22–gestational week (gw) brains and super-resolution scanning, we identified a large proliferative microglial aggregate (2.129 mm2) near the lateral ganglionic eminence (>12.5 gw), expanding in Down’s syndrome (DS) (4.767 mm2) and Edwards syndrome (ES) (3.437 mm2) fetal brains. Ki67+ microglia within the aggregates accounted for 26.65% (DS: 38.9%; ES: 46.3%) compared with 6.32% (DS: 6.01%; ES: 5.2%) in scattered microglia. This aggregate region contained a distinct microglial population characterized by the absence of phagocytic structures and complex processes, high CSF-1R expression, abundant IL-34+ cells, and some SPP1+ bipolar microglia. We termed this structure the secondary microglial formation center (SMFC). Chimeric microglia–human cortical organoids recapitulated the SMFC in an IL-34– and CSF-1R–dependent manner, indicating that the human SMFC may compensate for the microglial shortage during the fastest expansion period.
- Open Access
Secondary microglia formation center in the human fetal brain
Yolk sac-derived microglia migrate and populate the brain during development, constituting 10−15% of the total brain cells. The human brain is the largest and most complex brain with the highest cognitive capacity among all species. Therefore, the limitations of rodent brain studies in interpreting the human brain are evident. By co-immunostaining microglia in 50 µm fetal brain sections from 7.5 to 16 gestational weeks (gw) and combining high-resolution scanning, we identified a highly proliferative microglia aggregate (0.108−2.129 mm 2 ) that expanded in Down’s Syndrome fetal brain (4.168 mm 2 ) and was located near the ganglion eminence, in which Ki67 + microglia accounted for 23.4% of total microglia compared to 6.3% in other brain regions. The microglia in the aggregates lack phagocytic bulbs, membrane ruffles, and long/branching processes compared to microglia in other brain regions. Introducing human microglia into cortical organoids, but not macrophages, replicated proliferative microglial aggregates on the brain organoid surface and sufficiently penetrated deeper regions of the cortical organoids. Penetrating microglia display phagocytic capacity, enhance immunity, and accelerate the maturation of brain organoids. The large proliferative microglial aggregate may be a unique secondary microglial formation center in the human fetal brain to compensate for the enormous microglial demands during brain expansion.
Open AccessSecondary microglia formation center in the human fetal brain
Yolk sac-derived microglia migrate and populate the brain during development, constituting 10−15% of the total brain cells. The human brain is the largest and most complex brain with the highest cognitive capacity among all species. Therefore, the limitations of rodent brain studies in interpreting the human brain are evident. By co-immunostaining microglia in 50 µm fetal brain sections from 7.5 to 16 gestational weeks (gw) and combining high-resolution scanning, we identified a highly proliferative microglia aggregate (0.108−2.129 mm 2 ) that expanded in Down’s Syndrome fetal brain (4.168 mm 2 ) and was located near the ganglion eminence, in which Ki67 + microglia accounted for 23.4% of total microglia compared to 6.3% in other brain regions. The microglia in the aggregates lack phagocytic bulbs, membrane ruffles, and long/branching processes compared to microglia in other brain regions. Introducing human microglia into cortical organoids, but not macrophages, replicated proliferative microglial aggregates on the brain organoid surface and sufficiently penetrated deeper regions of the cortical organoids. Penetrating microglia display phagocytic capacity, enhance immunity, and accelerate the maturation of brain organoids. The large proliferative microglial aggregate may be a unique secondary microglial formation center in the human fetal brain to compensate for the enormous microglial demands during brain expansion.
- Open Access
- 1 September 2020
- Published by Elsevier in Stem Cell Reports
- Vol. 15 (3) , 761-775
“Reprogram Enablement” as an Assay for Identifying Early Oncogenic Pathways by Their Ability to Allow Neoplastic Cells to Reacquire an Epiblast State
- 1 September 2020
- Published by Elsevier in Stem Cell Reports
- Vol. 15 (3) , 761-775
Open Access“Reprogram Enablement” as an Assay for Identifying Early Oncogenic Pathways by Their Ability to Allow Neoplastic Cells to Reacquire an Epiblast State
- 16 May 2014
- Published by Wiley in Current Protocols in Stem Cell Biology
- Vol. 29 (1) , 1C.16.1-1C.16.13
Generation, Expansion, and Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) Derived From the Umbilical Cords of Newborns
The umbilical cord is tissue that is normally discarded after the delivery of the infant, but it has been shown to be a rich source of stem cells from the cord blood, Wharton's jelly, and umbilical endothelial cells. Patient‐specific human induced pluripotent stem cells (hiPSCs) reprogrammed from patient specific human umbilical vein endothelial cells in the neonatal intensive care unit (NICU) population (specifically, premature neonates) have not been shown in the literature. This unit describes a protocol for the generation and expansion of hiPSCs originating from umbilical cords collected from patients in the NICU. Curr. Protoc. Stem Cell Biol. 29:1C.16.1‐1C.16.13. © 2014 by John Wiley & Sons, Inc. Keywords: umbilical cord; HUVEC; reprogramming; iPS
- 16 May 2014
- Published by Wiley in Current Protocols in Stem Cell Biology
- Vol. 29 (1) , 1C.16.1-1C.16.13
Generation, Expansion, and Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) Derived From the Umbilical Cords of Newborns
The umbilical cord is tissue that is normally discarded after the delivery of the infant, but it has been shown to be a rich source of stem cells from the cord blood, Wharton's jelly, and umbilical endothelial cells. Patient‐specific human induced pluripotent stem cells (hiPSCs) reprogrammed from patient specific human umbilical vein endothelial cells in the neonatal intensive care unit (NICU) population (specifically, premature neonates) have not been shown in the literature. This unit describes a protocol for the generation and expansion of hiPSCs originating from umbilical cords collected from patients in the NICU. Curr. Protoc. Stem Cell Biol. 29:1C.16.1‐1C.16.13. © 2014 by John Wiley & Sons, Inc. Keywords: umbilical cord; HUVEC; reprogramming; iPS